Association for the Advancement of Restorative Medicine

Psychedelic plant medicines such as Ayahuasca and Huachuma (San Pedro cactus) are gaining scientific attention for their potential to improve mental health. However, the interplay between these traditional medicines, the gut microbiome, and mental health outcomes remains underexplored.

The main objectives of this study are to investigate the effects of Ayahuasca and Huachuma ceremonies on the gut microbiome, depression, and subjective connectedness in a single patient and to generate hypotheses for future studies.

A 35-year-old female with prior psychedelic experience participated in separate Ayahuasca and Huachuma ceremonies. Qualitative data were collected through patient interviews. Quantitative data included stool samples collected before and after each ceremony for microbiome analysis, as well as survey data using the Hamilton Depression Rating Scale (HAM-D) and Watts Connectedness Scale (WCS) administered pre- and post-ceremony.

Both ceremonies resulted in substantial reductions in depression scores (HAM-D decreased: Ayahuasca from 18 to 6; Huachuma from 12 to 2) and connectedness scores (WCS increased: Ayahuasca from 62.3% to 95.37%; Huachuma from 58.32% to 84.65%). Although Ayahuasca and Huachuma induced different gut microbial composition shifts, reductions in pro-inflammatory taxa, normalization of inflammation-linked bacterial species, and increases in beneficial butyrate-producing bacterial species were observed for both. These microbial shifts aligned with improved subjective mental health and reduced inflammation. Qualitative interviews revealed distinct archetypal experiences with each medicine, informing personalized therapeutic approaches.

This hypothesis-generating case study illustrates a potential link between psychedelic-induced microbiome changes and improvements in mental health which may contribute to reduced inflammation and sustained antidepressant effects via the microbiota–gut–brain axis.

With over one in five U.S. adults facing a diagnosable psychiatric condition, mental health remains a critical frontier in integrative care. However, pharmacological management often falters; nearly 50% of patients discontinue medication due to intolerable side effects like weight gain and emotional blunting. This guide bridges that gap, utilizing a robust body of clinical evidence — from double-blind RCTs to mechanistic studies — to demonstrate how specific botanicals and amino acids can effectively modulate neurotransmitter systems with a significantly lower adverse effect burden.

Iodine is an indispensable component in the biosynthesis of the thyroid hormones thyroxine (T4, prohormone) and triiodothyronine (T3, active hormone). Iodine must be obtained through the diet, as the body is unable to produce it. The risks posed by iodine deficiency are well recognized, but more widespread use of biomarkers for iodine status has demonstrated that iodine deficiency is still evident within subpopulations in high income countries, including areas with low goiter prevalence, and even in regions where iodine deficiency was considered eradicated.